Week in Review: Jibeier Pharma Files to Raise $100 Million in IPO on New Shanghai STAR Board

Deals and Financings • Jibeier Pharm of Jiangsu filed to raise $100 million in an IPO on Shanghai's new Science and Technology Innovation Board to support its chemical drug, TCM and API business; • South Korea's Yuhan out-licensed rights for its dual agonist NASH treatment to Boehringer Ingelheim in an agreement worth up to $870 million; • The parent of Hutchison China MediTech (Chi-Med) sold $288 million of its Chi-Med stake, reducing its holdings to about 50%, worth about $1.5 billion; • Lepu Biotech, a Shanghai immunotherapy company that is a division of Lepu Medical, raised $131 million in an A round financing led by Shiyu Capital; • Zai Lab of Shanghai entered a $77.5 million collaboration to develop Incyte's PD-1 mAb in Greater China, which it will pair with its other oncology drugs; • Asieris MediTech of Taizhou acquired global rights to Cevira®, a treatment for cervical lesions, from Photocure of Oslo in an deal worth up to $73 million; • Zhongyianke Biotech, a Tianjin vaccine maker, raised $36 million in a Series A financing to develop its portfolio of human vaccines; • Shanghai Synyi Medical Technology completed a $36 million C funding round to support its AI-based big data healthcare operations; • Ocumension, a Hong Kong ophthalmology company, acquired China rights to a treatment for acute blepharitis from France's Nicox in a $13.5 million agreement. Stock Symbols: (KRX: 000100) (AIM/NSDQ: HCM) (NSDQ: ZLAB) (NSDQ: INCY) (OSE: PHO) (Paris: FR0013018124) Share this with colleagues: // //